# ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

> **NCT02044120** · PHASE1 · COMPLETED · sponsor: **Sarcoma Alliance for Research through Collaboration** · enrollment: 34 (actual)

## Conditions studied

- Ewing Sarcoma

## Interventions

- **DRUG:** niraparib
- **DRUG:** Temozolomide
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT02044120
- **Lead sponsor:** Sarcoma Alliance for Research through Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2021-01
- **Final completion:** 2021-01
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02044120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02044120, "ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02044120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*